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Abstract
Wound healing is an active and compound biological course which can be 
divided into four steps: hemostasis, inflammation, proliferation, and remodeling. 
Diabetes mellitus induces weakened wound healing by disturbing one or more of 
the biological functions of these steps. Diabetic foot ulcers result from the simul-
taneous action of multiple disturbing causes. Mesenchymal stem cells, especially 
autologous ones, are easily accessible with noninvasive methods and have been 
shown to provide a regenerative microenvironment at wound sites. Despite current 
knowledge, major hurdles remain to be overcome in order to achieve effective thera-
peutic effects. Photobiomodulation is the use of light to reduce pain and inflamma-
tion and stimulate healing and the proliferation of stem cells, which would be very 
useful in increasing stem cell function and in regenerative medicine. The current 
study analyzes the results of studies using separate and combined administrations 
of stem cells and photobiomodulation on diabetic wound healing in patients and 
animal models. We hypothesize that the combined application of photobiomodula-
tion and stem cells will accelerate the repair process and assist the healing of foot 
ulcers in diabetes mellitus patients.
Keywords: wound healing, diabetes mellitus, diabetic foot ulcers,  
mesenchymal stem cells, adipose tissue-derived stem cells, photobiomodulation
1. Introduction
Diabetes mellitus (DM) is the most important cause of illness and death, affect-
ing 422 million adults worldwide [1]. Epidemiological studies of DM in the U.S. have 
shown that almost one out of every three people in the U.S. is prone to preDM or 
suffering from DM. The Centers for Disease Control and Prevention (CDC) recently 
reported that more than 100 million adults in the U.S. have DM or pre-DM. In 2015, 
a total of 30.3 million people of all ages, or 9.4% of the U.S. populace, were reported 
to have DM. Moreover, a total of 33.9% of the U.S. adults aged 18 years or older (84.1 
million people) had pre-DM in 2015. Almost half (48.3%) of adults aged 65 years 
or older have pre-DM which, if left untreated, will develop into Type 2 DM within 
5 years [2]. Of the entire population of the U.S., 33% are predicted to be afflicted by 
DM by the year 2050 [3]. Diabetic foot ulcer (DFU) is still the predominant cause of 
hospitalization for patients with DM, and DM is the chief reason for more than 50% 
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of nontraumatic leg amputations. Obviously, these operations increase the death 
ratio [3].
In this chapter notes are provided about the following subjects: 2, acute wound 
healing in healthy subjects; 3, a mechanistic approach to wound healing in DM; 4, 
DFU;5, administration of stem cells in DFUs; 6, adipose tissue-derived stem cells 
(ADSC); 7, regenerative potential of ADSC; 8, PBM and its effects on cells and stem 
cells; 9, how the combined application of photobiomodulation (PBM) and ADSCs 
accelerates healing in DFU; and 10, finally we will deliver our conclusions in section 10.
2. Acute normal skin injury repair course in healthy subjects
The acute normal skin injury repair course can be separated into four overlying 
steps: 1. coagulation; 2. inflammation; 3. proliferation; and 4. remodeling. During 
the first step, blood-clotting actions preclude extreme hemorrhage and deliver tem-
porary protection to the injured area. The development of inflammation directs the 
use of leukocytes, neutrophils, and macrophages; the creation of growth factors; 
and the stimulation of fibroblasts, keratinocytes, and angiogenesis. Achievement 
of the proliferation step in wound repair directs the creation of extracellular matrix 
(ECM), i.e. rich, vascularized granulation tissue. Lastly, ECM maturation and cell 
apoptosis direct the creation of scar tissue with physical features that are similar 
to unwounded skin [4]. The repair of an acute skin injury comprises synchronized 
cellular and molecular responses. First, immune cells migrate to the injury site, 
then they initiate pathogen clearance, while also participating in the repair course. 
Cut epidermal borders upregulate wound-related genes, thereby allowing mutual 
cell migration. Local and blood-borne fibroblasts increase and migrate to produce 
wound granulation tissue, provide organization and signaling clues, and deliver 
new ECM. Some fibroblasts differentiate into myofibroblasts to help wound closure. 
The wound bed is perfused with oxygen and nutrients through new blood vessels 
derived by angiogenesis [5].
3. A mechanistic approach to wound healing in DM
DM causes the repair course directed to a non-healing wound (chronic 
wound or ulcer) to lag, resulting in practical restrictions, gait trouble, and 
contamination. The weakening of repair in DM patients is well-known, but 
the connection between pathophysiology and weakened skin injury repair in 
DM is still an unidentified etiology. The repair course requires cooperation 
between inflammatory cells and biochemical mediators encouraged by many 
elements. Nevertheless, alterations in the cellular and biochemical elements and 
accomplishments are concerns associated with wound healing failure in DM 
patients. Neutrophils, monocytes, macrophages, keratinocytes, fibroblasts, T 
and B cells, mast cells, and endothelial cells all contribute to wound repair and 
dynamically to the creation and regulation of various cytokines and growth 
factors. Monocytes, which later transform into macrophages, are the principal 
manufacturers of pro-inflammatory cytokines, including interleukin-1 (IL) -1β, 
tumor necrosis factor (TNF)-α, IL-6 and cytokines, and growth factors such as 
vascular endothelial growth factor (VEGF), insulin-like growth factor (IGF)-1, 
and transforming growth factor (TGF) - β in both healthy and diabetic subjects. 
Neutrophils, such as T and B cells, are also important producers of TNF-α and 
IL-10 cells among others, keratinocytes, fibroblasts, mast cells, and endothelial 
cells which participate in the production of VEGF, IGF-1, and TGF-β.
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Macrophages are fundamental providers in healing. Hyperglycemia and oxida-
tive stress alter the epigenetic code that results in alterations to the polarization 
and plastination of macrophages. Dysregulated macrophage polarization is one 
of the key hindrances to wound repair. Investigations have revealed that in DM, 
a compound function is included at the molecular level which is accountable for 
hindered wound repair. Actions like the continued production of pro-inflammatory 
cytokines, weakened angiogenic response and microvascular difficulties, weakened 
macrophage and neutrophils function, weakened keratinocytes and fibroblast 
migration, and increased and weakened creation of healing-associated elements 
like decreased growth factor creation have been reported in animal simulations of 
DM. The steps of the remedial course in diabetic sufferers are also delayed (in the 
inflammatory stage) by other elements as well as specific metabolic insufficien-
cies, weakened functional responses like hypoxia due to glycation of hemoglobin, 
and changes in red blood cell membranes and the tapering of blood vessels. 
Hypoxia reduces the oxygen stream to wounds because of tapering blood vessels. 
Hemoglobin glycation causes a lack of nutrients and oxygen to tissue, which further 
interrupts the repair course. Diabetic wounds continuously stimulate the unfolded 
protein response (UPR) and increase expression of pro-inflammatory chemokine 
in comparison with normal wounds. Native ischemia because of microvascular 
problems in DM significantly delays the repair course [6].
Reduced IGF-1 and TGF-β values at sites of tissue injury have been described 
in both diabetic animals and human (h) s with DM and are accountable for 
delayed repair to skin injuries. TGF-β employs and encourages the motivation 
of inflammatory cells, including neutrophils, macrophages, and lymphocytes, 
as well as keratinocytes, fibroblasts, and the creation of growth factors, which 
hasten neovascular formation, and the creation and delayed deterioration of 
ECMs. The decreased attentiveness of TGF-β has been described in skin injury 
repair in diabetic subjects. Many studies have proven that matrix metalloprotein-
ase (MMP)-encoding genes have a TGF-β1-dependent preventative component 
in the promoter region, which down-regulates expression of the gene. Reduced 
TGF-β values and improved expression of MMPs induce the extreme deterioration 
of growth factors. Accompanied by MMP-encoding genes, transcription factors 
like Smad-2, Smad-3, and Smad-4 also trigger and suppress TGF-β target genes. 
TGF-β1 triggers Smad-2 and 3 for the creation of collagen. Reductions in TGF-β1 
values augment the use of triggered inflammatory cells to hinder progression from 
the inflammatory step to the proliferation step in the repair course of diabetic 
wounds. Elevated TGF-β3 values are supposed to reduce TGF-β1 values in diabetic 
subjects, which leads to augmented macrophage action and reduced collagen 
creation. In DM, elevated glucose levels increase macrophage action, directing 
more reactive oxygen species (ROS) to extend the inflammatory step. Reduced 
values and expression of these growth factors weaken and extend the skin injury 
repair course in DM [6].
4. DFU
Disturbances in the coordination of glucose homeostasis induce hyperglycemic 
prominence and result in the initiation of certain metabolic pathways that, in their 
unusual situation, lead to the progression of vascular deficiency, nerve damage 
caused by ulcerations in inferior limbs because of changed patterns of plantar pres-
sure, and consequently foot abnormalities. Abuse to the foot produced by trauma to 
the affected area remains hidden to the patient because of damage to afferent sen-
sory nerves [7]. Diabetic neuropathy results in foot muscular inequality, inadequate 
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feeling in the skin, and ultimately foot irregularities that lead to augmented force 
applied to the skin when walking. Collectively, the above-mentioned occurrences 
are accompanied by foot ischemia [8] and DFU formation.
When a foot ulcer develops, the foot is at increased risk for aggressive infec-
tion, and as soon as it is combined with a peripheral artery occlusive disease, 
the sufferer will have dangerous foot ischemia [8]. Thus, the etiology for DFU is 
composite. Disruption of harmony in glucose homeostasis causes hyperglycemic 
status, results in activation of certain metabolic pathways which in their abnormal 
state subsequently leads to development of vascular insufficiency, nerve damages 
headed by ulceration in lower extremity due to plantar pressures and foot defor-
mity. Staphylococcus is the most common infectious bacterium [9]. A diabetic foot 
infection may be a warning limb complaint. Infection is identified by the occur-
rence or augmented ratio of inflammation markers. Frequently, these markers 
are less noticeable than anticipated. Imaging investigations can identify or better 
define profound, soft tissue-infected areas and are regularly required to detect 
pathological results in bone. The primary bactericidal cure as well as the length of 
cure are observational. There is a considerable delay in DFU injury repair that has 
been correlated to many irregularities [9]. Today, DM is the chief origin of non-
traumatic amputations in the U.S. Generally, around 5% of DM patients develop 
DFUs, and 1% of them wind up with an amputation. Around 60% of diabetic 
patients will develop neuropathy, ultimately leading to a DFU. The danger of a DFU 
is augmented in people with flatfoot, as they apply uneven pressure across the foot, 
leading to local inflammation in risky areas of the foot. The yearly occurrence of 
DFU ranges from 9.1 to 26.1 million cases globally, and about 15% to 25% of DM 
patients will develop a DFU sometime during their lifespan.
As the number of newly identified DM cases rises annually, the occurrence 
of DFU is also destined to rise. DFUs are accountable for higher medical charges 
than any other diabetic difficulty. The usual cost of curing one DFU is $8,000, 
that of an infected DFU is $17,000, and that of a chief amputation is $45,000. 
Over 80,000 amputations are done yearly on diabetic patients in the U.S., 
and approximately 50% of patients with amputations will develop ulcers and 
infections in the other foot within 1.5 years. Sadly, 58% of people with DM will 
experience a second amputation 3–5 years after the first one. Furthermore, the 
prevalence of death occurring 3 years after a first amputation has been estimated 
to be as high as 20%–50%, and these statistics have not altered considerably in 
the past 30 years despite major developments in the medicinal and surgical man-
agement of DM patients [10]. Management of DFUs is mainly based on severity 
(score), blood vessel status, and the existence of contamination. Inhibiting the 
reappearance of DFUs remains a chief medical objective [11]. Numerous novel 
cures correlated to these aberrations have been discovered in wound repair with 
differing achievements [9].
5. Administration of mesenchymal stem cells (MSC) in DFUs
As previously described, DFUs are one of the more frequent and severe dif-
ficulties of DM, as wound repair is weakened in the diabetic foot. Investigations 
concentrated on comprehensively understanding these functions could allow for 
a precisely directed cure for DFUs. The main treatments for DFUs are currently 
wound debridement, weight off-loading, neovascularization, and contamination 
treatment. Nevertheless, some DFUs are extremely impervious to routine cures, and 
the development of wound repair remains to be the goal of numerous cure policies. 
Novel cure choices such as bioengineered skin substitutes, ECM proteins, cytokines, 
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and negative pressure wound therapy, have been developed as supplementary rem-
edies for DFUs [12]. Stem cell therapies have appeared as top-notch cure methods 
with the possibility of returning tissue to its pre-injury state.
The use of cellular therapy in the treatment of skin injuries is presently a 
dynamic field of research. Multi-potent adult stem cells are an attractive option for 
cell therapy, as they have a high possibility of proliferation and the capability of 
differentiating into diverse cell types and creating a range of cytokines and growth 
factors essential to wound repair. This study concentrated on the involvement of 
three types of adult stem cell populations through a skin injury repair course and 
their beneficial possibilities for use in cell therapy.
Endothelial progenitor cells (EPCs) are endothelial precursors involved in the 
revascularization of injured tissue and tissue repair. Their vascular repairing potentials 
have been described in a range of translational and human investigations into ischemic 
illnesses, together with myocardial infarction, stroke, and peripheral arterial illness. 
Furthermore, numerous articles have stated that EPC engraftment can enhance 
wound repair by improving new blood vessel formation in granulation tissue. It has 
been reported that the administrated EPCs released a variety of wound repair-related 
growth factors and cytokines, thus encouraging the implementation of monocyte/
macrophage and exciting endogenous new blood vessel formation during the course 
of skin injury repair. Another study showed that the transplantation of human cluster 
of differentiation (CD) 133+ progenitor cells into streptozotocin-induced diabetic mice 
amplified the wound closure rate and capillary density in granulation tissues. These 
results suggest that EPC engraftment would be favorable for the cure of skin wounds, 
specifically chronic wounds which are often connected with reduced peripheral blood 
flow and continue to be tough to heal using existing beneficial tactics [13].
Bone marrow-derived mesenchymal stem cells (BM-MSCs), comprise another 
talented nominee for the reparation or substitution of injured tissue. BM-MSCs 
have the ability to differentiate into numerous lineages, such as endothelial cells, 
neural cells, and hepatocytes, among others. Furthermore, research has shown 
that BM-MSCs participate in wound repair by differentiating into numerous 
cutaneous cell types. It has further been reported that BM-MSCs differentiate into 
keratinocytes, endothelial cells, pericytes, and monocytes. One study reported that 
BM-MSCs significantly improved wound repair in both diabetic and nondiabetic 
mice; BM-MSC-treated wounds displayed augmented wound contraction by dis-
charging proangiogenic elements including VEGF and angiopoietin-1. Analysis of 
paracrine elements released from BM-MSCs with real-time polymerase chain reac-
tion (PCR) and of BM-MSC-CM by enzyme-linked immunosorbent assay (ELISA) 
showed that BM-MSCs secreted VEGF, IGF-1, epidermal growth factor (EGF), 
keratinocyte growth factor (KGF), angiopoietin-1, and stromal derived factor 
(SDF)-1. These paracrine elements from MSC-condition media (CM) displayed a 
pronounced influence in utilizing CD14+ monocytes, keratinocytes, and endothelial 
cells in injured tissue, thus encouraging the skin injury repair course [13].
6. Adipose tissue-derived stem cells (ADSCs)
ADSCs are placed inside the stromal vascular fraction of adipose tissue. They 
have the ability to differentiate into adipogenic, osteogenic, chondrogenic, and 
myogenic cells when they are cultivated in particular culture circumstances. New 
information has shown the possible effects of ADSCs on new blood vessel formation 
in ischemic illness animal simulation. ADSCs discharge numerous powerful anti-
genic elements and were also shown to collaborate in angiogenesis by differentiating 
into endothelial cells in an in vivo study. The engraftment of ADSCs is reported to 
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encourage wound contraction and enhance blood perfusion in injured skin. When 
ADSCs were cultivated in hypoxic circumstances, they released VEGF 5-time more 
than in normoxic circumstances [13].
In regenerative medicine, adult stem cells are the greatest encouraging cell types 
for cell-based therapies. Human adipose tissue has been presented as a novel origin 
for multipotent stem cells. These so-named ADSCs are considered perfect for use in 
regenerative therapies. Their chief benefit over MSC extracted from other origins, e.g., 
from bone marrow, is that they can be simply and repeatable collected using negligibly 
aggressive methods with little injury. ADSCs are multipotent and can differentiate 
into numerous cell types. Interestingly, ADSCs are categorized by immunosuppressive 
properties and have little immunogenicity. Their discharge of trophic elements make 
compulsory the healing and regenerative results in an extensive variety of administra-
tions. Generally, these specific characteristics of ADSCs make them very much appli-
cable for medical uses. Therefore, the beneficial probability of ADSCs is huge [13].
7. Regenerative potential of adipose tissue-derived stem cells
The beneficial impacts of ADSCs have been determined to be valuable in 
regenerative therapies for many illnesses. Specifically, ADSCs can be collected, 
handled, and cultured in a nominally aggressive, yet calm and persuasive method, 
and they have the great probability of differentiating into mature cells along the 
mesodermal, ectodermal, and endodermal lineages. Throughout recent years, 
crucial advancements have been made concerning the separation, morphological 
features, molecular biology, and in vitro differentiation potential of stem cells, 
and it has become clear that ADSCs might facilitate beneficial effects. Not only do 
they act as tissue-specific progenitor cells, but they also participate in a number of 
chief functions, e.g., paracrine-mediated signaling of angiogenesis, inflammation, 
cell homing, and cell survival. The above-mentioned essential results have assisted 
us in gradually closing the hole between basic knowledge and clinical application; 
meanwhile, ADSCs have been used in clinical trials all over the globe, presenting as 
harmless and realistic options in a range of simulations.
Nevertheless, before ADSCs can be used in conventional medical administra-
tions, numerous obvious queries associated with ADSCs must be resolved. With the 
intention of fully appreciating the fundamental functions which control ADSCs, 
future experimentations should, for example, concentrate on additional accurate 
markers for the improved and source-precise classification of ADSCs. Moreover, 
the genetic alteration of ex vivo-cultivated cells should not be ignored, and the 
controllers concerning differentiation, migration, and cell viability after in vivo 
engraftment must be clarified. Furthermore, as the scientific comprehension of 
the regenerative capabilities and, therefore, the potential uses of ADSCs increases, 
the possible dangerous threats must be addressed, and the supervisory outline that 
directs their medical usage must be established. Presently, precise supervisory 
instructions are set by the country in which treatment occurs. Clearly, the world-
wide standardization of rules of use is crucial. In conclusion, scientific advance-
ments, supervisory rules, and a commercial substructure are all vital factors in the 
development and conversion of this talented MSC origin [14].
Conversely, there are some methodological questions for the application of 
MSCs and ADSCs for skin regeneration in DM patients, as discussed below.
1. The elevated extracellular glucose density in diabetic wounds leads to the 
collection of advanced glycosylation end products (AGEs). The creation of 
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AGEs prevents proliferation, leads to hADSCs apoptosis, prevents the dif-
ferentiation, proliferation, and homeostasis of ADSCs into endothelial cells, 
and also prevents the production of collagen protein, ultimately hindering 
wound repair [15].
2. Despite the rising usage of MSCs in medicinal human research, the curative 
benefit continues to be insignificant [16]. This is partially related to the nor-
mal, limited disease-modifying ability of MSCs [16]. At the same time, tissue 
destruction and the remedial response lead to the excretion of interior danger 
signals [17], comprising Toll-like receptors (TLRs) and interleukin-1 recep-
tors, type 1 (IL-1R1) ligands, that alter the immune microenvironment [18]. 
TLRs and IL-1R1 unfavorably impress the cure of numerous injured organs [19]. 
IL-1R1/myeloid differentiation primary response 88 (MYD88) signaling un-
favorably regulates bone repair in mice by injuring the regenerative abilities of 
murine MSCs. Furthermore, IL-1b that is released at bone injury areas inhibits 
the regenerative abilities of MSCs [20]. Thus, new approaches to increasing the 
strength of MSCs is an active area of life science research with medical impor-
tance [16]. MSCs have been one of the profoundly investigated options for cell 
therapy. As the homing ability of MSCs is a key influential element of effective 
MSC-based cures, the progress of homing effectiveness is important for creat-
ing faultless, positive outcomes. Therefore, tactics to stimulate and reinforce 
the function, mobilization, and homing of MSCs have advanced a key option in 
regenerative medicine [21].
3. Stem cell numbers have been reduced in some animal simulations of skin 
damage. Wu et al. observed a significant rise in the survival of stem cells 7 days 
after inducing skin damage and a quick reduction in cell viability 14 days after 
damage [22]. Muhammad et al. presented that the engraftment of ADSCs has-
tens the course of acid burn skin injury repair [23].
8. PBM and its effect on cells and stem cells
The term “LASER” originated as an acronym for “light amplification by stimu-
lated emission of radiation.” Laser radiation could encourage a photobiomodula-
tory impact on cells and tissues, participating in a concentrating inflection of cell 
behaviors, increasing the courses of tissue repair. PBM, also recognized by its 
former term low-level laser therapy (LLLT), is a safe technique that participates in 
pain reduction and decreases inflammation, along with improving cure and tissue 
healing. It also encourages cell propagation and increases stem cell differentiation 
[24]. PBM is a fast-developing technology applied many medical situations where 
stimulus of repair, decrease in pain and inflammation, and renovation of action 
are needed. While skin is obviously exposed to light more than any other organ, it 
still reacts fine to red and near-infrared wavelengths. The photons are absorbed by 
mitochondrial chromophores in skin cells. Therefore, electron transport, adenosine 
triphosphate nitric oxide release, blood flow, ROS increase, and various signaling 
paths are triggered. Stem cells can be activated, permitting augmented tissue repair 
and healing [25]. PBM, with its above-mentioned properties, can mediate numer-
ous illnesses and circumstances, such as DM, brain damage, spinal cord injury, 
dermatological circumstances, oral annoyance, and diverse fields in dentistry. Most 
studies have reported a rise in the propagation ratio of radiated cells [24]. PBM 
definitely controlled the in vitro propagation of the ADSC examined, and new in 
Wound Healing
8
vitro documents have been presented where PBM meaningfully augmented hAD-
SCs cell survival in comparison to control and PBM-treated hBM-MSC groups [26].
9.  How the combined application of PBM and ADSCs can accelerate  
DFU healing
Concerning the low viability ratio of ADSCs transplanted onto a wound, 
the application of some superior pretreatment agents not only makes available 
a good biological circumstance for the transplanted ADSC, but also encourages 
their propagation, differentiation, and paracrine capabilities and causes them to 
discharge more cytokines and growth factors [27]. Because PBM can augment the 
proliferation ratio of cultivated ADSCs [26], it can be considered as an effective 
approach for the preconditioning of ADSCs in in vitro situations preceding ADSC 
transplantation. In Zare et al. study [26] both in vitro human bone marrow-derived 
mesenchymal stem cells (hBM-MSCs) and h adipose-derived stem cells (hADSCs) 
were irradiated with 36 protocols using two different laser types (helium-neon [He-
Ne] and diodes), four different laser wavelengths (HeNe laser, 630 nm, 810 nm, 
630 + 810 nm); three different energy densities (0.6 J/cm2, 1.2 J/cm2, 2.4 J/cm2); and 
three different PBM times (1, 2, and 3). A total of 1 × 104 MSCs were seeded in each 
well of a 24 well-plate. Next, the He–Ne laser at 632.8 nm, (IR-2000; IAEA, Tehran, 
Iran), red laser at 630 nm, NIR laser at 810 nm, and 630 nm +810 nm (NILTVIR202 
Noura Instruments, Tehran, Iran) were applied. It should be mentioned that 
immediately after switched on the laser machine, it was ready for PBM therapy. In 
order to ensure exposure of the entire well (15.6 mm well) to PBM, the He–Ne laser 
emission was expanded by an optic culminator and the spot size of the red and NIR 
lasers were increased by a cone shaped pine hole culminator. Control MSCs did not 
receive PBM. Table 1 lists the PBM protocol specifications.
Zare et al. study [26] demonstrated that PBM with the combined 630 + 810 nm 
lasers significantly stimulated 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay which was measured the effects of PBM on MSC viability, 
and significantly decreased population doubling time (PDT) and apoptosis rate of 
hBM-MSCs and hASDCs in vitro. There were no pharmacological side effects of PBM 
on MSC as evidenced by measuring apoptosis rate of MSCs. Zare et al. reported new 
in vitro evidence where PBM administered at 630 nm (one and two times, 0.6 and 1.2 
J/cm2) and 630 + 810 nm (three times, 2.4 J/cm2) significantly increased hADSC cell 
viability compared to its control and the PBM-treated hBM-MSC groups. PBM-based 







































Specifications of the photobiomodulation (PBM) protocol.
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Accordingly, Ahmadi et al. examined the efficiency of several preconditioned ADSCs 
and PBM regimes on healing an infected ischemic delayed-healing wound in type 1 
diabetic rats. Their study included five groups of rats: (1) control, (2) control ADSCs 
[diabetic ADSCs were engrafted into the wound bed], (3) ADSCs + PBM in vivo (dia-
betic ADSCs were transplanted into the wound, followed by in vivo PBM therapy), (4) 
ADSCs + PBM in vitro, and (5) ADSCs + PBM in vitro + in vivo.
Ahmadi et al. for in vitro study seeded a total of 1 × 104 passage-4 ADSCs in 
each well of a 24-well plate for each of three groups: healthy control ADSC, diabetic 
control ADSC, and experimental diabetic ADSC. Here, red laser alone plus infrared 
laser alone (NILTVIR202 Noura Instruments, Tehran, Iran) at two energy densities 
(1.2 J/cm2 and 2.4 J/cm2) were used to irradiate the ADSC every other day for three 
sessions according to a previously published protocol. Ahmadi et al. found that 
diabetic ADSCs preconditioned with PBM had significantly increased the MSC 
viability, and significantly decreased PDT, and apoptotic rate of ADSCs in compari-
son with diabetic ADSCs. Table 2 lists the in vitro, and in vivo   PBM parameters. 
The control ADS did not receive PBM. The wounds of the rats in groups 3 and 5 
were subjected to PBM in vivo (Figure 1).
























Red 630 0.05 46 1.2 1.56 1.91 0.0261
Near infrared 810 0.05 46 1.2 1.56 1.91 0.0261
Specifications of in vivo photobiomodulation
Parameters Dose and unit









Duration of exposure for each point 200 s
Energy density 0.2 J/cm2
Number of laser shootings in each session 9
Energy densities for one session and for 
the total sessions
1.8 and 25.2 J/cm2
PBM radiation scheduling Immediately after surgery, 6 days per week, for 16 
consecutive days
Probe L07
Company MUSTANG 2000, Technica Co., Russia
Table 2. 
Specifications of in vitro and in vivo photobiomodulation parameters.
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Table 2 lists the complete specifications of the PBM protocols for invitro and in 
vivo studies. There were no pharmacological side effects of PBM on MSC in Ahmadi 
et al. study as evidenced by histological examination of wounds.
Groups 3 and 5 showed significant reductions in bacterial contamination 
compared to groups 1 and 2. Groups 2, 3, 4, and 5 showed significantly enhanced 
wound contraction ratios in comparison with group 1. Groups 2–5 displayed 
Figure 1. 
A photo of the wound, photobiomodulation (PBM) target points, and adipose tissue -derived stem cell 
(ADSCs) injection points.
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significantly increased wound strength compared to group 1.In most cases, 
group 5 had significantly better results than groups 2, 3, and 4. Ahmadi et al. 
concluded that preconditioning diabetic ADSCs with PBM in vitro plus PBM in 
vivo significantly accelerated healing in the diabetic rat model of an ischemic 
infected delayed-healing wound [29]. In other related studies, the same results 
were reported. Khosravi et al. reported that the in vitro preconditioning of 
hADSCs with PBM significantly amplified bone repair in a rat model of critical 
size femoral defect in vivo [30]. Liao et al. explored the therapeutic potential of 
hADSCs preconditioned with PBM. Cultured ADSCs were treated with PBM. In 
addition, a mouse photoaged skin simulation was proven by UVB radiation. Liao 
et al. concluded that PBM is a persuasive bioenhancer of ADSCs and may improve 
the healing possibility of ADSCs for medical use [31]. While few studies give some 
evidence for the positive effects of PBM alone for wounds in diabetic patients 
[32], or PBM plus skin grafts for burn ulcers in diabetic patients [33, 34], there 
have been no clinical trials using human models to show stem cells plus PBM as an 
effective agent in wound care regimes to date. Further well designed clinical trials 
are necessary to determine the true value of ADSCs plus PBM in routine wound 
care regimes for patients with DM.
10. Conclusions
Present knowledge dictates that when an organ is healthy, the inflammatory 
phase of wound healing is well orchestrated, lasting only a few days, and the steps 
of tissue repair proceed normally. However, when an organ is hyperglycemic, as 
with DM, the inflammatory process is extended, the integrity of the skin is not 
restored, and DFU occurs. DFUs are a serious clinical problem and affect millions 
of people around the world. They need repetitious cures, impose extensive medical 
expenses, and create a major economic burden on healthcare systems worldwide. 
Thus, much work has been concentrated on evolving new healing approaches for 
wound treatment. Preclinical studies have shown that preconditioning diabetic 
ADSCs with PBM in vitro significantly increases ADSC function over that of 
diabetic ADSCs. Preconditioning diabetic ADSC with PBM significantly hastened 
healing in ischemic MRSA–infected, delayed-healing wounds in rats with type one 
DM compared to the control, ADSC alone, and ADSC plus PBM-in vivo rats. The 
combined administration of preconditioned diabetic-ADSC with PBM plus PBM 
therapy in vivo demonstrated a significantly superior effect compared to other 
treatment protocols [29].
Whereas our hypothesis (combined application of PBM and stem cells can 
accelerate repairing process and assist healing DFU in animal models and patients) 
was confirmed through preclinical studies [29, 30, 31], we suggest further animal 
and clinical trial investigations be conducted in order to provide more documenta-
tion. Hopefully these outcomes would help the use of ADSCs plus PBM as a routine 
treatment protocol for the healing of severe DFU in patients with DM.
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